Seroprevalence of hepatitis a virus antibody in 11-15 years old children in Vijayawada and age-related incidence of hepatitis a virus in GGH, Vijayawada

Authors

  • Srimukhi Anumolu Department of Paediatrics, Siddhartha Medical College, Vijayawada, Andhra Pradesh, India
  • Kireeti Jarjapu Department of Paediatrics, Siddhartha Medical College, Vijayawada, Andhra Pradesh, India
  • M. A. Rahman Department of Paediatrics, Siddhartha Medical College, Vijayawada, Andhra Pradesh, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20210649

Keywords:

Seroprevalence, Hepatitis-A, Anti HAV Ig G, Hepatitis-A vaccine

Abstract

Background: To estimate seropositivity of hepatitis A virus Ig G antibody (HAV Ig G antibody) in 11 to 15 years aged children in Vijayawada.

Methods: The study group includes 265 consecutive children aged 11 to 15 years attending GGH, Vijayawada and had a blood sample taken for any reason. The serum samples collected were screened for Anti HAV IgG antibody using commercially available Elisa kit (WANTAI). Information related to various socio demographic factors also were elicited by interview method. All the Anti-Hepatitis A virus IgM antibody positive individuals list are collected from 1stJuly 2015 to 1st august 2017 and were categorized based on age and analysed.

Results: The total seropositivity against Hepatitis A virus is 71%. The number of children in the urban population showing IgG antibodies is lower compared to that of rural population (p value-0.028). The highest number of Hepatitis A virus infected population (positive IgM) is between 10-14 years (50), followed by 15-19 years (45) and 5-9 years (43). This shows that there is increased risk of infection in the older age group and there is a shift to 2nd and 3rd decade (p value – 0.045).

Conclusions: The seropositivity of HAV IgG antibody in children aged 11-15 years is 71% in Vijayawada. Seroprevalence in the nearby area, Chennai, ten years back was found to be 95% by 12 years of age. This indicates there is a shift from high to intermediate endemicity in Vijayawada. There is need for vaccination in the susceptible individuals.

 

Author Biography

Srimukhi Anumolu, Department of Paediatrics, Siddhartha Medical College, Vijayawada, Andhra Pradesh, India

Assistant Professor of Pediatrics, Siddhartha medical college

References

Rezende G, Roque-Afonso AM, Samuel D, Gigou M, Nicand E, Ferre V, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology. 2003;38:613-18.

Rosenblum LS, Villarino M, Nainan OV, Melish ME, Hadler SC, Pinsky PP, Jarvis WR, et al. Hepatitis an out-break in a neonatal intensive care unit; risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis. 1991;164:476-82.

Das K, Jain A, Gupta S, Kapoor S, Gupta RK, Chakravorty A, et al. The changing epidemiological pattern of hepatitis a in an urban population of India: emergence of a trend similar to European countries. Eur J Epidemol. 2000;16(6):507-10.

Mohanavalli B, Dhivehi E, Menon T, Malathi S, Thyagarajan SP. Prevalance of antibodies to hepatitis A and hepatitis E virus in urban school children in Chennai. Indian Pediatr 2003;40:328-31.

Mathew P, Bobba R, Zacharis P. Hepatitis-A seroprevalence in Kerala. Indian J Gastroenterol. 1998;17:S71-2.

Mathur P, Arora NK. Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries. Indian J Med Res. 2008;128:699-704.

Arankalle VA, Chadha MS, Chitambar SD, Walimbe AM, Chobe LP, Gandhe SS. Changing epidemiology of hepatitis A and E in urban and rural India. J Viral Hepat. 2001;8:293-303.

Lee D, Cho YA, Park Y, Hwang JH, Kim JW, Kim NY, et al. Hepatitis A in Korea; epidemiological shift and call for vaccine strategy. Intervirology. 2008;51(2):70-4.

Havens WP. The ethology of infectious hepatitis. JAMA. 1947;34:653-5.

Callum MFO. Homologous serum jaundice. Lancet. 1947;2:691-2.

Krugman S, Giles JP, Hammond DJ. Infectious hepatitis; evidence for two distinctive clinical, epidemiological, and immunologic types of infection. JAMA. 1967;200:365-73.

Koff RS. Hepatitis A. Lancet 1998;351:1643-9.

Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a good review and analysis. Epidemiol Infect. 2004;132:1005-22.

Global prevalence of hepatitis A virus Infection and susceptibility: A systematic review.www.who.int/vaccines-documents.

World Health Organization. Hepatitis A. WHO/CDS/CSR/EDC/2000.7.

Bell BP, Feinstone SM, Hepatitis A vaccine. In: Plotkin SA, Orienstein WA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders. 2004;269-97.

Kim YJ, Lee HS. Increasing incidence of hepatitis-A in Korean adults. Intervirology. 2010;53(1):10-4.

Downloads

Published

2021-02-23

Issue

Section

Original Research Articles